AmerisourceBergen's U.S. Bioservices posts banner year

Press enter to search
Close search
Open Menu

AmerisourceBergen's U.S. Bioservices posts banner year

By Michael Johnsen - 02/07/2018
US Bioservices, an independent specialty pharmacy and a part of AmerisourceBergen, on Wednesday announced that 2017 was a record breaking year for new business wins in three strategic areas – oncology, rare and orphan and specialty infusion. US Bioservices received access to 28 new products in 2017, including 10 oncology products and three rare and orphan therapies.

“Patients struggling with cancer and managing rare diseases require very specialized, clinically-coordinated care and service. We understand the critical expertise and commitment required to deliver solutions and support to patients who benefit from specialized therapies,” Kelly Ratliff, president of US Bioservices, said. “We were built ... on providing high-acuity pharmacy and nursing support. Because we began as a home infusion pharmacy – providing infusion and nursing services to patients upon discharge from an acute care setting – we have a unique understanding of, and appreciation for, the level of care our patients need and deserve. We continue to align our investment and innovation strategies to ensure that we remain a premier partner in support of oncology and rare disease patient populations.”

Operating out of Frisco, Texas, US Bioservices leverages the breadth and depth of resources provided by AmerisourceBergen companies, including Lash Group for patient support services; ION Solutions and Oncology Support for their connections to community oncology providers and ICS and ASD Healthcare for rare and orphan logistics and distribution expertise.

US Bioservices supports AmerisourceBergen customers’ access to specialty products that are critical to improving outcomes and the patient experience across the continuum of care, from oncology practices to health system specialty pharmacies and community pharmacies.